INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Submission of Matters to a Vote of Security Holders

84

INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders


The Company held its Annual Meeting on June 19, 2017. A total of
120,191,807 shares of Common Stock, representing 79.84% of the
shares outstanding and eligible to vote and constituting a
quorum, were represented in person or by valid proxies at the
Annual Meeting. The final results for each of the matters
submitted to a vote of shareholders at the Annual Meeting are as
follows:

Proposal 1: All of the nominees for the Board of Directors were
elected and will hold office until a successor is elected and
qualified, or until the Director resigns, is removed or becomes
disqualified, by the votes set forth below:


Nominee


For


Withheld


Broker Non-Votes


Dr. Bassam Damaj, Ph.D


59,933,711


987,707


59,270,389


Dr. Henry Esber, Ph.D


60,108,816


812,602


59,270,389


Vivian Liu


60,095,516


825,902


59,270,389


Dr. Ziad Mirza, M.D.


60,108,011


813,407


59,270,389

Proposal 2: The appointment of Hall Company, Inc. as the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017 was ratified by the Companys
shareholders by the votes set forth in the table below:


For


Against


Abstain


115,063,862


4,749,162


378,783

Section 8 Other Events

Item 8.01 Other Events

On June 20, 2017, the Company announced that in order to expand
its sales and marketing team in preparation of its launch of
FlutiCareTM in the 4th Quarter of 2017, Robert C. Verfurth has
been appointed the Vice President of Sales and Marketing.
Verfurth came back to Innovus Pharma after spending the previous
two years building a commercial team and launching a new
blood-based colon cancer technology at Applied Proteomics, Inc.
He was also part of the Innovus Pharma team back in 2013 in a
similar role. Mr. Verfurth was also part of the marketing and
sales team at Apricus Biosciences (NASDAQ: APRI), a specialty
pharmaceutical company. Prior to Apricus, Mr. Verfurth was Vice
President, US Sales-West for Becton Dickinson Diagnostics. Before
that, he served as Vice President, US Sales and Support for the
molecular diagnostic start-up GeneOhm Sciences beginning in 2005.
GeneOhm Sciences was purchased by Becton Dickinson, after which
Mr. Verfurth continued his sales leadership responsibilities in
the molecular and infectious disease product areas. Prior to
GeneOhm, Mr. Verfurth held a number of commercial roles,
including Vice President of Sales at both Prometheus Laboratories
and Dianon Systems. He also spent six years in the United States
Air force, achieving the rank of Captain. Mr. Verfurth earned a
Bachelor of Science degree in Business Administration from the
University of Notre Dame and a Master’s of Science degree in
Systems Management from the University of Southern California



About INNOVUS PHARMACEUTICALS, INC. (OTCMKTS:INNV)

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

An ad to help with our costs